Helen Killick
AstraZeneca (Brazil)(BR)AstraZeneca (Switzerland)(CH)
Publications by Year
Research Areas
IL-33, ST2, and ILC Pathways, Eosinophilic Esophagitis, Asthma and respiratory diseases, Immune Cell Function and Interaction, Pediatric health and respiratory diseases
Most-Cited Works
- → Oxidised IL-33 drives COPD epithelial pathogenesisviaST2-independent RAGE/EGFR signalling complex(2023)74 cited
- → A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease(2023)38 cited
- → Neutrophil GM-CSF receptor dynamics in acute lung injury(2019)28 cited
- → Nasal IL-13 production identifies patients with late-phase allergic responses(2023)17 cited
- → Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease(2024)12 cited
- → IL-33 is associated with alveolar dysfunction in patients with viral lower respiratory tract disease(2024)8 cited
- → Altered Differentiation and Inflammation Profiles Contribute to Enhanced Innate Responses in Severe COPD Epithelium to Rhinovirus Infection(2022)7 cited
- → Proof of Mechanism for Anti-Interleukin-33 Antibody Tozorakimab in a Phase 1 Study in Healthy Adults and Patients with Chronic Obstructive Pulmonary Disease(2022)6 cited
- → Safety, Pharmacokinetics and Immunogenicity of the Anti-Interleukin-33 Antibody, Tozorakimab: Results of a Phase 1 Study in Healthy Adults and Patients with Chronic Obstructive Pulmonary Disease(2022)4 cited
- → Novel assays to measure forms of interleukin-33 in the circulation and airway mucosa(2019)4 cited